Ophthalmology Times

Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
Ophthalmology Times

Clinical and Biologic Distinctions in Managing Retinal Vascular Diseases

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...
Ophthalmology Times

Defining Retinal Vascular Diseases AMD, DME, RVO

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...
Ophthalmology Times

EyePoint receives second consecutive positive recommendation from DSMC

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...
Ophthalmology Times

Coave Therapeutics reveals lead gene therapy program, CoTx-101

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...